← All trials
NCT07181109
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2025
- Primary completion
- Oct 29, 2030
- Completion date
- Oct 29, 2030
- First posted
- Sep 18, 2025
- Last posted
- Nov 4, 2025
- Enrollment
- 11000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alnylam PharmaceuticalsLead sponsor
- RocheCollaborator
- Alnylam PharmaceuticalsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.